Loading
Geneplus' personalised blood test found relapse months before scans in bowel, breast and lung cancer, and the mutations shared by every tumour cell were the most informative.
The assay profiles the tumour with a comprehensive genomic panel, selects up to 20 top-ranked variants for a personalised panel and integrates it with a tumour-naive cancer-type fixed panel for ultra-deep plasma sequencing. Its sample-level limit of detection reaches as low as 0.005 per cent with 100 per cent specificity. In colorectal, breast and lung cancer it predicted postoperative recurrence before imaging by a median of 112 days in breast and 83 days in lung cancer. Among tracked variants, clonal mutations showed more prognostic value than subclonal ones.
Subclonal variants are seen less often in residual disease than clonal ones, which is what limits attributing what is left to a subclone.
Shares Naming which clone or phenotype is left after treatment, Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Geneplus personalised MRD assay, Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares Naming which clone or phenotype is left after treatment, Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/